Novartis has expanded its partnership with Monte Rosa Therapeutics by acquiring exclusive rights to a new molecular glue degrader candidate for immune diseases, along with options for two additional preclinical programs. The deal includes $120 million upfront and potential milestones totaling $5.7 billion, emphasizing Novartis's commitment to developing targeted protein degradation therapies. Monte Rosa intends to utilize the funds to advance multiple Phase 2 trials, including treatments for autoimmune and inflammatory diseases. This collaboration builds on a previous 2024 agreement focused on VAV1-targeting degraders intended for cancer and autoimmune indications.